Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
Abstract Number: 0195 • ACR Convergence 2020
Epidemiology and Characteristics of Incident Rheumatoid Arthritis in Persons with and Without HIV
Jennifer Hanberg¹, Kathleen Akgun², Liana Fraenkel³, Evelyn Hsieh² and Amy Justice⁴, ¹Yale University School of Medicine; West Haven VA, Boston, MA, ²Yale University School of Medicine; West Haven VA, New Haven, CT, ³Yale School of Medicine; West Haven VA; Berkshire Medical Center, Lenox, MA, ⁴Yale University School of Medicine; Yale School of Public Health; West Haven VA, West Haven, CT
Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory arthritis, affecting 1-2% of the population. Estimates of the incidence of RA in patients with…
Abstract Number: 0211 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
Xiaofeng Zeng¹, Dongbao Zhao², Sebastiao Radominski³, Mauro Keiserman⁴, Chang Keun Lee⁵, Sebastian Meerwein⁶, Jeffrey Enejosa⁷, Yunxia Sui⁷, Mohamed-Eslam Mohamed⁷ and Won Park⁸, ¹Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ²Shanghai Changhai Hospital, Shanghai, China (People's Republic), ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Pontificial Catholic University, Porto Alegre, Brazil, ⁵Asan Medical Center, Seoul, Republic of Korea, ⁶Pharmaceutical Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸Inha University, Incheon, Republic of Korea
Background/Purpose: This Phase 3, randomized, double-blind, placebo (PBO)-controlled study assessed the efficacy and safety of upadacitinib (UPA) in combination with csDMARDs in patients with rheumatoid…
Abstract Number: 0228 • ACR Convergence 2020
Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study
Eduardo Mysler¹, Yoshiya Tanaka², Arthur Kavanaugh³, Daniel Aletaha⁴, Peter Taylor⁵, In-Ho Song⁶, Tim Shaw⁶, Yanna Song⁷, Ryan DeMasi⁶, Mira Ali⁶ and Roy Fleischmann⁸, ¹Organización Medica de Investigación, Buenos Aires, Argentina, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁵Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago,, IL, ⁸Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In the randomized, double-blinded, Phase 3 SELECT-COMPARE study, upadacitinib (UPA) + MTX demonstrated greater clinical and functional responses vs adalimumab (ADA) + MTX in…
Abstract Number: 0431 • ACR Convergence 2020
Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients
Elizabeth Park¹, Jon Giles², Thania Perez-Recio¹, Paloma Pina³, Christopher Depender¹, Joan Bathon¹ and Laura Geraldino-Pardilla⁴, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Columbia University, New York, NY, ³Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
Abstract Number: 0488 • ACR Convergence 2020
Incidence of Dementia in Patients with Rheumatoid Arthritis and Association with DMARDs – Analysis of a National Claims Database
Sebastian Sattui¹, Iris Navarro-Millan², Fenglong Xie³, Mangala Rajan², Huifeng Yun⁴ and Jeffrey R Curtis⁴, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: There is growing interest regarding the role of neuroinflammation in the development of dementia and the potential role for anti-inflammatory therapy, including TNF-inhibitors (TNFi),…
Abstract Number: 0635 • ACR Convergence 2020
Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients
Bonnia Liu¹, Victor Yang², Christopher McMaster³, Russell Buchanan⁴, Albert Frauman⁵ and David Liew⁶, ¹Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, ²Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, ⁴Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, ⁵Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, ⁶Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
Abstract Number: 0753 • ACR Convergence 2020
Synovial Tissue Histopathology Findings in Early RA. Is It Useful? Analysis of the Belgian CAP48 Cohort
Stéphanie de Montjoye¹, Tatiana Sokolova¹, Emilie Sapart¹, Bernard Lauwerys², Stéphanie Dierckx³, Christine Galant⁴, Laurent Meric de Bellefon¹, Adrien Nzeusseu Toukap⁵, Clément Triaille⁶ and Patrick Durez⁷, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ³Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ⁴3Pathology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁵1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁶Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: Rheumatoid arthritis is a heterogeneous disease with different clinical presentation and prognostic factors including the immune process in the synovium. The development of ultrasound-guided…
Abstract Number: 0770 • ACR Convergence 2020
Effect of Citrullination on the Processing and Presentation of Rheumatoid Arthritis Autoantigens
Ashley Curran¹, Jonathan Crawford¹ and Erika Darrah¹, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Citrullinated proteins are hallmark targets of the autoimmune response in rheumatoid arthritis (RA), but the mechanism by which immune tolerance is broken to these self-proteins…
Abstract Number: 0787 • ACR Convergence 2020
MerTK Synovial Expression Correlates with Disease Activity and Treatment Response in Rheumatoid Arthritis Patients
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Giulia Maria Ghirardi², Gloria Lliso-Ribera², Felice Rivellese¹, Myles Lewis¹, Michele Bombardieri², Frances Humby² and Costantino Pitzalis², ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom
Background/Purpose: Despite valuable improvements in long-term clinical outcomes, a significant portion of rheumatoid arthritis (RA) patients still do not adequately respond to available treatments, and…
Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Elise van Mulligen¹, Saad Ahmed¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…
Abstract Number: 0821 • ACR Convergence 2020
Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Vijaya Rivera¹, Sandra Sicsik Ayala¹, David Vega Morales², Fedra Irazoque-Palazuelos³, Dafhne Miranda Hernández¹, Julio Casasola Vargas¹, Sandra Carrillo Vázquez¹, Angélica Peña Ayala¹, Angel Castillo Ortiz¹, Omar Muñoz Monroy¹, Sergio Durán Barragán¹, Aleni Paz Viscarra¹, Estefanía Torres Valdez¹, Daniel Xibille Friedmann¹, Erick A Zamora Tehozol⁴, Luis Valdés Corona¹, Azucena Ramos Sánchez¹, Natalia Santana Portillo¹, Francisco Guerrero Díaz¹, Miguel Vazquez Zaragoza¹, Claudia Zepeda Moreno¹, Kitzia Alvarado Sánchez¹, Melanea Rivera Valencia¹, Cesar Pacheco Tena⁵ and Deshire Alpizar-Rodriguez⁶, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Universidad Autónoma de Nuevo León, Garcia, Mexico, ³Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, ⁴Centro Médico Pensiones, Merida, Yucatan, Mexico, ⁵Universidad Autonoma de Chihuahua, Chihuahua, Chihuahua, Mexico, ⁶Colegio Mexicano de Reumatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is the most common autoimmune disease and is more frequent and severe in women than in men. Symptom severity, disease progression,…
Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Daimon Simmons¹, Hung Nguyen², Emma Gomez-Rivas³, YunJu Jeong⁴, William Apruzzese⁵, Edy Kim⁶ and Michael Brenner⁷, ¹Department of Pathology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, ⁵., Boston, ⁶Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
Abstract Number: 1002 • ACR Convergence 2020
Prostate Cancer Risk Is Not Increased in Rheumatoid Arthritis After Accounting for Retention in a Health Care System
Kaitlyn Brittan¹, Punyasha Roul¹, Joshua Baker², Yangyuna Yang¹, Brian Sauer³, Namrata Singh⁴, Harlan Sayles¹, Grant Cannon⁵, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Utah, Omaha, NE, ⁴University of Washington, Bellevue, WA, ⁵Salt Lake City VA Medical Center and University of Utah, Salt Lake City
Background/Purpose: Patients with rheumatoid arthritis (RA) may have up to a 15% increased risk of prostate cancer per a recent meta-analysis (Simon et al. Arthritis…
Abstract Number: 1018 • ACR Convergence 2020
Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)
Lijun Wu¹, Zhanyun Da², Hongzhi Wang³, Jianlin Huang⁴, Bin Wu⁵, Henglian Wu⁶, Fang He⁷, Fen Wang⁸, Rong Du⁹, Linchong Su¹⁰, Qiaoqiao Yao¹¹, Rui Wu¹², Zhenbin Li¹³, Xiaohan Wang¹⁴, Yuhong Liu⁹, Chuanjing Li¹⁵, Xiaomei Lei¹⁶, Minjun Wang¹⁷, Hui Xiao¹⁷, Yuhua Jia¹⁸, Yihong Liu¹⁷, Xin Chen¹⁷, Shengsong Jia¹⁷, Bing Wu¹⁸, Yuan Liu¹⁷, Fei Xiao¹⁸ and Lingli Dong¹⁹, ¹People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ²The affiliated Hospital of Nantong University, Nantong, Jiangsu, China (People's Republic), ³The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁴The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁵Chongqing Hospital of Traditional Chinese Medicine, chongqing, Chongqing, China (People's Republic), ⁶Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ⁷Suining Central Hospital, Suining, Sichuan, China (People's Republic), ⁸The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁹Union Hospital Affiliated Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁰Minda Hospital of Hubei Minzu University, Enshi, Hubei, China (People's Republic), ¹¹China Resources Wuhan Iron and Steel General Hospital, Wuhan, Hubei, China (People's Republic), ¹²The First Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ¹³Chinese people ’s liberation army joint service support force 980 hospital, shijiazhuang, Jiangxi, China (People's Republic), ¹⁴Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁵Xiaogan Central Hospital of Hubei Province, Xiaogan, Hubei, China (People's Republic), ¹⁶Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China (People's Republic), ¹⁷Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁹Tongji Hospital Affiliated to Tongji Medical College of HUST, Wuhan, Hubei, China (People's Republic)
Background/Purpose: Treat-to-Target(T2T) is the main therapeutic strategy for patients with RA and SLE. There has been no report on comparation of seasonal variations on T2T…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].